ClinicalTrials.gg
CompletedNCT00399568Updated Oct 21, 2016Results posted

Efficacy and Safety of Intravenous Acetaminophen Over 48 Hrs for the Treatment of Post-op Pain After Gynecologic Surgery

A Phase 3 interventional study of IV Acetaminophen and IV Placebo 100 mL solution in Postoperative Pain and Hysterectomy, sponsored by Mallinckrodt. Completed at 27 sites in United States. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-10-21.

Sponsored by Mallinckrodt · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
331
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 118 studies testing acetaminophen in Pain, Postoperative — 11 open to participants now, 13 under way, 1 of them phase 3. Acetaminophen · Pain, Postoperative.

Enrollment
11th of 118
331 · median 90
Started
2006
with 3 others
Phase 3
20 of 118
1 open now
Registered
3rd of 118
by date
Lead sponsor
3 of 118
Mallinckrodt

Among the 118 studies testing acetaminophen in Pain, Postoperative, this one is the 11th largest by enrollment, is one of 4 that started in 2006, is one of 20 in phase 3, and was the 3rd registered.

Pain, Postoperative

5,671 studies on the registry are indexed under Pain, Postoperative; 1,241 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

11 of the 118 studies testing acetaminophen in Pain, Postoperative are open now, in 4 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 677 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies testing acetaminophen in Pain, Postoperative, or all of them as a file.
02

Study summary

This study will be investigating the efficacy and safety administration of multiple doses of intravenous (IV) acetaminophen (IVAPAP) in the 48 hour period following Gynecologic Surgery.

Read the detailed description

The research hypothesis is that IV Acetaminophen will provide greater reduction in pain intensity and greater pain relief for moderate and severe pain as compared to placebo in the 48 hours following surgery.

03

Conditions studied

  • Postoperative Pain
  • Hysterectomy

Keywords

  • Pain
  • Gynecologic
  • IV Acetaminophen
  • Postoperative
  • Analgesic
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Undergo gynecologic surgery using standard abdominal approach such as midline or Pfannenstiel incision
  • 18-75 years of age
  • (BMI) between 19-45
  • (ASA) risk class of I, II, III
  • Not have received neuraxial (spinal or epidural) opioid analgesics prior to or during surgery
  • Moderate to Severe pain at rest

Exclusion criteria

Exclusion Criteria:

  • Requires any additional surgical procedures either related or unrelated to gynecologic surgery during same hospitalization
  • Procedures involving only minimal incisions such as laparotomy, laparoscopy, supraumbilical or Maylard incisions
  • Has know to opioids, acetaminophen, or the of IV acetaminophen
  • Known history of alcohol or drug abuse or misuse
  • Has impaired liver function (AST), Alanine aminotransferase(ALT), greater than or equal to 2 times
  • Has significant medical disease(s), or conditions that may contraindicate participation in the study
  • Has participated in another clinical trial within 30 days of surgery
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
331 participants (actual)

Study arms

  • Experimental
    IV acetaminophen 1 g/100 mL solution

    Drug: IV Acetaminophen

  • Placebo comparator
    IV Placebo 100 mL solution

    Drug: IV Placebo 100 mL solution

Interventions

  • Intravenous acetaminophen 1 g/100 mL

    Also known as: IV Acetaminophen (IV APAP)

  • DrugIV Placebo 100 mL solution

    IV Placebo 100 mL solution dosed at same frequency as IV Acetaminophen every 6 hours (q6h)

    Also known as: IV Placebo (non-active product)

06

What researchers measure

Primary outcomes

  1. Sum of Pain Intensity at Rest-Baseline to 24 Hours (SPI24rest), 1 Gram IV Acetaminophen vs. Placebo.

    The Sum of Pain Intensity (SPI) score incorporates the analgesic effects on pain intensity (PI) from Baseline to 24 hours. SPI was measured by the 100 millimeter (mm) long Visual Analog Scale (VAS) over 24 hours after treatment. Subjects were asked to mark the level of pain they were experiencing at a certain timepoint on the scale The 100mm VAS scale was used with the left terminus (0 mm) of the scale "No Pain" and the right terminus (100 mm) with "Worst Pain Imaginable". The range of measurement is 0-2400 mm for 24 hours.

    Time frame: Baseline (just prior to the first dose) through 24 hours

  2. Sum Pain Intensity at Rest-Baseline to 48 Hours (SPI48rest), 1 Gram IV Acetaminophen vs. Placebo

    The Sum of Pain Intensity (SPI) score incorporates the analgesic effects on pain intensity (PI) from Baseline to 48 hours. SPI was measured by the 100 millimeter (mm) long Visual Analog Scale (VAS) over 48 hours after treatment. Subjects were asked to mark the level of pain they were experiencing at a certain timepoint on the scale The 100 mm VAS scale was used with the left terminus (0 mm) of the scale "No Pain" and the right terminus (100 mm) with "Worst Pain Imaginable". The range of measurement is 0-4800 mm for 48 hours.

    Time frame: Baseline (just prior to the first dose) through 48 hours

Secondary outcomes

  1. Subjects Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)

    Number of subjects who experienced at least one treatment emergent adverse event (TEAE) A TEAE is an adverse event that occurs on or after administration of the first dose of study medication (T0)

    Time frame: First dose through 7 day follow up

  2. Subjects Who Experienced at Least One Treatment-emergent Serious Adverse Event.

    Number of subjects who reported SAEs during the study. A serious Adverse event (SAE) is defined as any untoward medical occurence at any dose of study medication that: Results in Death, Is Life Threatening, Requires inpatient hospitalization or causes prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, or Is an important medical event

    Time frame: 32 days following first dose of study medication.

07

Results

Posted Dec 10, 2010

Participant flow

Gynecologists and/or anesthesiologists were selected to participate as Principal Investigators.

Participant flow — Overall Study
MilestoneIV Acetaminophen 1 g/100 mL SolutionIV Placebo 100 mL Solution
Started166165
Completed154156
Not completed129
Withdrew: Adverse event12
Withdrew: Withdrawal by subject73
Withdrew: Protocol non-compliance22
Withdrew: Lost to follow-up22

Outcome measures

PrimarySum of Pain Intensity at Rest-Baseline to 24 Hours (SPI24rest), 1 Gram IV Acetaminophen vs. Placebo.

The Sum of Pain Intensity (SPI) score incorporates the analgesic effects on pain intensity (PI) from Baseline to 24 hours. SPI was measured by the 100 millimeter (mm) long Visual Analog Scale (VAS) over 24 hours after treatment. Subjects were asked to mark the level of pain they were experiencing at a certain timepoint on the scale The 100mm VAS scale was used with the left terminus (0 mm) of the scale "No Pain" and the right terminus (100 mm) with "Worst Pain Imaginable". The range of measurement is 0-2400 mm for 24 hours.

Time frame:
Baseline (just prior to the first dose) through 24 hours
Reported as:
Mean · units on a scale (in millimeters)
Sum of Pain Intensity at Rest-Baseline to 24 Hours (SPI24rest), 1 Gram IV Acetaminophen vs. Placebo.
units on a scale (in millimeters)IV Acetaminophen 1 g/100 ml SolutionIV Placebo 100 ml Solution
Sum of Pain Intensity at Rest-Baseline to 24 Hours (SPI24rest), 1 Gram IV Acetaminophen vs. Placebo.1793.3 ± 481.491845.3 ± 420.21
SecondarySubjects Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)

Number of subjects who experienced at least one treatment emergent adverse event (TEAE) A TEAE is an adverse event that occurs on or after administration of the first dose of study medication (T0)

Time frame:
First dose through 7 day follow up
Reported as:
Number · Subjects
Subjects Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)
SubjectsIV Acetaminophen 1g/100 ml SolutionIV Placebo 100 ml Solution
Subjects Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)141149
PrimarySum Pain Intensity at Rest-Baseline to 48 Hours (SPI48rest), 1 Gram IV Acetaminophen vs. Placebo

The Sum of Pain Intensity (SPI) score incorporates the analgesic effects on pain intensity (PI) from Baseline to 48 hours. SPI was measured by the 100 millimeter (mm) long Visual Analog Scale (VAS) over 48 hours after treatment. Subjects were asked to mark the level of pain they were experiencing at a certain timepoint on the scale The 100 mm VAS scale was used with the left terminus (0 mm) of the scale "No Pain" and the right terminus (100 mm) with "Worst Pain Imaginable". The range of measurement is 0-4800 mm for 48 hours.

Time frame:
Baseline (just prior to the first dose) through 48 hours
Reported as:
Mean · units on a scale (in millimeters)
Sum Pain Intensity at Rest-Baseline to 48 Hours (SPI48rest), 1 Gram IV Acetaminophen vs. Placebo
units on a scale (in millimeters)IV Acetaminophen 1 g/100 ml SolutionIV Placebo 100 ml Solution
Sum Pain Intensity at Rest-Baseline to 48 Hours (SPI48rest), 1 Gram IV Acetaminophen vs. Placebo3612.4 ± 966.663718.2 ± 829.21
SecondarySubjects Who Experienced at Least One Treatment-emergent Serious Adverse Event.

Number of subjects who reported SAEs during the study. A serious Adverse event (SAE) is defined as any untoward medical occurence at any dose of study medication that: Results in Death, Is Life Threatening, Requires inpatient hospitalization or causes prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, or Is an important medical event

Time frame:
32 days following first dose of study medication.
Reported as:
Number · Subjects
Subjects Who Experienced at Least One Treatment-emergent Serious Adverse Event.
SubjectsIV Acetaminophen 1 g/100 ml SolutionIV Placebo 100 ml Solution
Subjects Who Experienced at Least One Treatment-emergent Serious Adverse Event.1114

Adverse events

Collected over Adverse Events were reported from the start of study medication until the follow up visit on Day 7 (+/- 2 days). Serious Adverse Events were collected for 32 days following start of study medication. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IV Acetaminophen 1g/100 mL Solution—11/166 (6.6%)135/166 (81.3%)
IV Placebo 100 mL Solution—14/165 (8.5%)145/165 (87.9%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventIV Acetaminophen 1g/100 mL SolutionIV Placebo 100 mL Solution
Accidental overdoseInjury, poisoning and procedural complications1/1665/165
IleusGastrointestinal disorders1/1662/165
Pelvic abscessInfections and infestations0/1662/165
SeromaInjury, poisoning and procedural complications2/1660/165
PyrexiaGeneral disorders1/1661/165
Abdominal abscessInfections and infestations0/1661/165
Vaginal infectionInfections and infestations0/1661/165
Postoperative ileusInjury, poisoning and procedural complications0/1661/165
AtelectasisRespiratory, thoracic and mediastinal disorders0/1661/165
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/1661/165
Most frequent other events
Showing 10 of 13
Most frequent other events
EventIV Acetaminophen 1g/100 mL SolutionIV Placebo 100 mL Solution
NauseaGastrointestinal disorders96/16688/165
ConstipationGastrointestinal disorders48/16649/165
PyrexiaGeneral disorders19/16637/165
VomitingGastrointestinal disorders37/16628/165
FlatulenceGastrointestinal disorders21/16628/165
PruritisSkin and subcutaneous tissue disorders24/16621/165
HeadacheNervous system disorders22/16617/165
InsomniaPsychiatric disorders18/16610/165
DizzinessNervous system disorders10/16616/165
TachycardiaCardiac disorders8/16613/165

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)IV Acetaminophen 1 g/100 mL SolutionIV Placebo 100 mL SolutionTotal
<=18 years000
Between 18 and 65 years163161324
>=65 years347
Sex: Female, Male
Sex: Female, Male(Participants)IV Acetaminophen 1 g/100 mL SolutionIV Placebo 100 mL SolutionTotal
Female166165331
Male000
Region of Enrollment
Region of Enrollment(participants)IV Acetaminophen 1 g/100 mL SolutionIV Placebo 100 mL SolutionTotal
United States166165331
08

Study locations

27 sites
  • University of Alabama (Anesthesiology)
    Birmingham, Alabama 35249, United States
  • Helen Keller Hospital
    Sheffield, Alabama 35660, United States
  • Arizona Research Center, Inc (JC Lincoln)
    Phoenix, Arizona 85023, United States
  • Arizona Research Center, Inc. (Arrowhead)
    Phoenix, Arizona 85023, United States
  • Precision Trials
    Phoenix, Arizona 85032, United States
  • Arcadia Methodist Hospital
    Arcadia, California 91007, United States
  • Glendale Adventist Medical Center
    Glendale, California 91206, United States
  • Huntington Memorial Hospital
    Pasadena, California 91105, United States
  • Accurate Clinical Trials, Inc.
    San Clemente, California 92672, United States
  • Visions Clinical Research
    Boynton Beach, Florida 33414, United States
  • G and G Research, Inc.
    Fort Pierce, Florida 34950, United States
  • Century Clinical Research, INC
    Holly Hill, Florida 32117, United States
  • Nature Coast Clinical Research
    Inverness, Florida 34452, United States
  • University of Miami School of Medicine Dept. of Anesthesiology
    Miami, Florida 33136, United States
  • Treasure Coast Obstetrics and Gynecology
    Vero Beach, Florida 32960, United States
  • William Beaumont Hospital
    Royal Oak, Michigan 48073, United States
  • Cooper Anesthesia
    Camden, New Jersey 08103, United States
  • St. Peters University Hospital, Anesthesiology
    New Brunswick, New Jersey 08901, United States
  • Albany Medical College Dept. of Anesthesiology
    Albany, New York 11208, United States
  • Jacobi Medical Center (Albert Einstein College of Medicine)
    Bronx, New York 10461, United States
  • Weill Medical College
    New York, New York 10021, United States
  • Stony Brook Anesthesiology Health Sciences Cente
    Stony Brook, New York 11794, United States
  • The Ohio State University Medical Center
    Columbus, Ohio 43210, United States
  • Allegheny Pain Managment
    Altoona, Pennsylvania 16602, United States
  • Thomas Jefferson University Dept. of Anesthesiology
    Philadelphia, Pennsylvania 19107, United States
  • Memorial Herman/Memorial City Hospital
    Houston, Texas 77024, United States
  • Texas Woman's Hospital
    Houston, Texas 77024, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Sep 2007 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2010, 3 years 3 months after primary completion. A results delay was requested in Apr 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2006
First posted
Nov 15, 2006
Start
Nov 2006
Primary completionActual
Sep 2007
CompletionActual
Sep 2007
Results delay requested
Apr 3, 2009
Results first posted
Dec 10, 2010
Last update
Oct 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00399568
Lead sponsor
Mallinckrodt
Responsible party
Sponsor
First posted
Nov 15, 2006
Start date
Nov 2006
Primary completion
Sep 2007
Completion
Sep 2007
Results posted
Dec 10, 2010
Last update
Oct 21, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion